Search

Search Results

• PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce^1,2, C. Santoro¹, E. Baldacci¹, S. Ligia¹, R. Mormile¹, M. Biglietto¹, M. Totaro¹, F. R. Mauro¹, M. Breccia¹, A. Chistolini¹ | ¹Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; ²Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.313

  576

  PDF: 0
• 

  Restrained glycoprotein VI-induced platelet signaling by tyrosine protein phosphatases independent of phospholipase Cγ2

  Jingnan Huang, Delia I. Fernández, Jinmi Zou, Xueqing Wang, Johan W.M. Heemskerk, Ángel García

  11-10-2023

  https://doi.org/10.4081/btvb.2023.93

  830

  PDF: 330

• PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.319

  469

  PDF: 0
• 

  PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi¹, L. Pechlivani¹, A. Kosma¹, K. Lalechou¹, M.G. Siskos², D. Alivertis³, A.D. Tselepis¹ | ¹Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; ²Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; ³Department of Biological Applications and Technology, University of Ioannina, Greece

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.501

  347

  PDF: 73
• 

  PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven^1|9, E. Van Gansewinkel^5|10, J. De Bruijne², F. Eskens³, D. De Groot⁴, K. Hermans⁵, N. Mohammad⁶, F. Van Vilsteren⁷, C. Verslype⁸, W. Moris⁹, M. Roest¹⁰, B. De Laat¹⁰ , J. De Vos-Geelen⁵, M. Kramer^1|9 | ¹Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ²Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; ³Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁴Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; ⁵Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ⁶Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; ⁷Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; ⁸Digestive Oncology, University Hospitals Leuven, Belgium; ⁹Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁰Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.554

  266

  PDF: 77